Zhang Piqiang, Sun Deyun, Sun Xuemei, Li Hongjuan
Department of Pediatrics, Linyi People Hospital, No. 27, East Jiefang Road, Linyi, 276003, Shandong, China.
Eur J Med Res. 2020 Sep 16;25(1):42. doi: 10.1186/s40001-020-00442-1.
microRNA-381 is dysregulated in a variety of cancers. However, its clinical significance in pediatric acute myeloid leukemia (AML) is still unclear. The purpose of this study was to detect the expression level of miR-381 in pediatric AML patients and to explore its potential clinical significance.
The levels of miR-381 in bone marrow and serum of 102 pediatric AML patients were measured by quantitative real-time polymorperase chain reaction (qRT-PCR). The diagnostic value of serum miR-381 in pediatric AML patients was evaluated by the receiver operating characteristic (ROC) curve. A Chi square test was used to analyze the relationship between serum miR-381 and the clinical characteristics of patients. Cox regression analysis and Kaplan-Meier evaluated the prognostic value of serum miR-381 in patients. Finally, the proliferation of the cells was analyzed by the CCK-8 assay.
Compared with healthy controls, the levels of miR-381 in serum and bone marrow of pediatric AML patients were significantly decreased (P < 0.001). ROC curve showed that miR-381 could distinguish pediatric AML cases from normal controls. At the same time, the downregulation of miR-381 was associated with M7 in the French-American-British (FAB) classifications and unfavorable cytogenetic risks (P < 0.05). Low serum miR-381 levels were associated with poor overall survival of pediatric AML (log-rank test, P = 0.011) and poor relapse-free survival (log-rank test, P = 0.004). Cox regression analysis confirmed that reduced serum miR-381 was an independent predictor of poor prognosis in AML (HR = 3.794, 95% CI 1.3633-10.559, P = 0.011). In addition, low expression of miR-381 significantly reduced the proliferation of cells (P < 0.05).
All experimental results confirm that miR-381 has reduced bone marrow and serum expression in pediatric AML, and low levels of serum miR-381 have certain diagnostic and prognostic value in pediatric AML and may be a potential therapeutic target for AML.
微小RNA-381在多种癌症中表达失调。然而，其在儿童急性髓系白血病（AML）中的临床意义仍不清楚。本研究旨在检测儿童AML患者中miR-381的表达水平，并探讨其潜在的临床意义。
采用定量实时聚合酶链反应（qRT-PCR）检测102例儿童AML患者骨髓和血清中miR-381的水平。通过受试者工作特征（ROC）曲线评估血清miR-381对儿童AML患者的诊断价值。采用卡方检验分析血清miR-381与患者临床特征之间的关系。Cox回归分析和Kaplan-Meier评估血清miR-381对患者的预后价值。最后，通过CCK-8法分析细胞的增殖情况。
与健康对照相比，儿童AML患者血清和骨髓中miR-381水平显著降低（P < 0.001）。ROC曲线显示，miR-381可区分儿童AML病例与正常对照。同时，miR-381的下调与法国-美国-英国（FAB）分类中的M7以及不良细胞遗传学风险相关（P < 0.05）。血清miR-381水平低与儿童AML患者的总生存期差（对数秩检验，P = 0.011）和无复发生存期差（对数秩检验，P = 0.004）相关。Cox回归分析证实，血清miR-381降低是AML预后不良的独立预测因素（HR = 3.794，95%CI 1.3633 - 10.559，P = 0.011）。此外，miR-381低表达显著降低细胞增殖（P < 0.05）。
所有实验结果证实，miR-381在儿童AML中骨髓和血清表达降低，血清miR-381水平低在儿童AML中具有一定的诊断和预后价值，可能是AML的潜在治疗靶点。
